Advertisement

Topics

Roche’s Top-Selling Cancer Drug Approved in Faster Injection Form

12:05 EDT 23 Jun 2017 | Drug Discovery Development

The new formulation of rituximab can be administered in five to seven minutes via injection versus 90 minutes or longer with intravenous infusion.
Staff Author: 
Topics: 

Original Article: Roche’s Top-Selling Cancer Drug Approved in Faster Injection Form

NEXT ARTICLE

More From BioPortfolio on "Roche’s Top-Selling Cancer Drug Approved in Faster Injection Form"

Advertisement
Quick Search
Advertisement
Advertisement